Clinical Trial Update: Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

View source ↗

Summary

Radium-223 dichloride (BAY88-8223) trial in castration-resistant prostate cancer with bone metastases is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Prostatic Neoplasms | Status: NO_LONGER_AVAILABLE